These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20855862)

  • 1. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.
    Marsh RA; Vaughn G; Kim MO; Li D; Jodele S; Joshi S; Mehta PA; Davies SM; Jordan MB; Bleesing JJ; Filipovich AH
    Blood; 2010 Dec; 116(26):5824-31. PubMed ID: 20855862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
    Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
    Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
    Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
    Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
    Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
    Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
    Lounder DT; Khandelwal P; Chandra S; Jordan MB; Kumar AR; Grimley MS; Davies SM; Bleesing JJ; Marsh RA
    Biol Blood Marrow Transplant; 2017 May; 23(5):857-860. PubMed ID: 28219834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.
    Marsh RA; Rao K; Satwani P; Lehmberg K; Müller I; Li D; Kim MO; Fischer A; Latour S; Sedlacek P; Barlogis V; Hamamoto K; Kanegane H; Milanovich S; Margolis DA; Dimmock D; Casper J; Douglas DN; Amrolia PJ; Veys P; Kumar AR; Jordan MB; Bleesing JJ; Filipovich AH
    Blood; 2013 Feb; 121(6):877-83. PubMed ID: 23131490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.
    Cooper N; Rao K; Gilmour K; Hadad L; Adams S; Cale C; Davies G; Webb D; Veys P; Amrolia P
    Blood; 2006 Feb; 107(3):1233-6. PubMed ID: 16219800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoeitic stem cell transplantation: A single institution experience.
    Ali S; Wall DA; Ali M; Chiang KY; Naqvi A; Weitzman S; Gassas A; Gibson P; Brager R; Fernandez CV; Crooks B; Schechter T; Krueger J
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28477. PubMed ID: 33740322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
    Allen CE; Marsh R; Dawson P; Bollard CM; Shenoy S; Roehrs P; Hanna R; Burroughs L; Kean L; Talano JA; Schultz KR; Pai SY; Baker KS; Andolina JR; Stenger EO; Connelly J; Ramirez A; Bryant C; Eapen M; Pulsipher MA
    Blood; 2018 Sep; 132(13):1438-1451. PubMed ID: 29997222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
    Andersen NS; Bornhäuser M; Gramatzki M; Dreger P; Vitek A; Karas M; Michallet M; Moreno C; van Gelder M; Henseler A; de Wreede LC; Schönland S; Kröger N; Schetelig J;
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2823-2834. PubMed ID: 31468122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis.
    Kim H; Mizuno K; Masuda K; Sakurai M; Ara T; Naito K; Uehara Y; Yamamoto G; Osada M; Machida S; Horio T; Fukushima K; Mori Y; Ichinohe T; Fukuda T; Atsuta Y; Kataoka K
    Transplant Cell Ther; 2024 Apr; 30(4):419.e1-419.e12. PubMed ID: 38266963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.